Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.
about
Smallpox vaccines for biodefense: need and feasibilitySide-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primatesA36-dependent actin filament nucleation promotes release of vaccinia virusVaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycansStructural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 proteinThe Structure of the Poxvirus A33 Protein Reveals a Dimer of Unique C-Type Lectin-Like DomainsThe mature virion of ectromelia virus, a pathogenic poxvirus, is capable of intrahepatic spread and can serve as a target for delayed therapy.A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infectionKinetics and intracellular location of intramolecular disulfide bond formation mediated by the cytoplasmic redox system encoded by vaccinia virus.The immunology of smallpox vaccines.Vaccinia virus exhibits cell-type-dependent entry characteristics.Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000.Host-based antipoxvirus therapeutic strategies: turning the tablesEpitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R.A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in miceThe 1.51-Angstrom structure of the poxvirus L1 protein, a target of potent neutralizing antibodies.Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors.Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection.The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 proteinCombinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challengeA protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.The myristate moiety and amino terminus of vaccinia virus l1 constitute a bipartite functional region needed for entryThe identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins.Evaluating the orthopoxvirus type I interferon-binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model.The inability of vaccinia virus A33R protein to form intermolecular disulfide-bonded homodimers does not affect the production of infectious extracellular virus.Epitope mapping by random peptide phage display reveals essential residues for vaccinia extracellular enveloped virion spread.Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus.Ligand-induced and nonfusogenic dissolution of a viral membrane.Capturing the natural diversity of the human antibody response against vaccinia virusEffect of the deletion of genes encoding proteins of the extracellular virion form of vaccinia virus on vaccine immunogenicity and protective effectiveness in the mouse model.Smallpox vaccines: targets of protective immunity.Vaccine-induced protection against orthopoxvirus infection is mediated through the combined functions of CD4 T cell-dependent antibody and CD8 T cell responses.Human T-cell responses to vaccinia virus envelope proteins.Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organsParainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs
P2860
Q22305942-13D1A060-CB3C-474D-BEF5-EB3E095AB0E6Q27325586-19243090-1D59-424D-B6BA-6FA1F305D564Q27335617-9E6BF5A1-3A62-4381-9F95-D5BA5CCCFDB0Q27488704-FAF50F26-10C5-4483-A358-B2842D937F86Q27647102-B35594AD-80AC-4587-8BDC-3DA4A60B75BCQ27658759-17D5831A-CE33-4E47-9012-21CAAFA558EDQ30223108-79517353-7D8F-4B87-8EF4-318A8087C674Q30445071-422FBB29-E457-42C8-B747-9CAEDDED6D09Q33302672-EFE91989-CB26-482E-950F-3D15C64C020DQ33664851-7E65C669-5634-4503-B6F9-1D731FAA2C26Q33679943-E988C1A6-79FF-430F-A602-EB6B9C9E3975Q33698769-DEB23933-ED50-4B0C-AB96-D41405E365C6Q33725635-BDB89E9B-AF5D-447C-912C-08BE0A4CDF44Q33743444-849AF215-8BB7-4731-8FC9-08AD55C9B5C0Q33777910-4795ECD1-6C54-405A-B85C-2C0218D841D4Q33780553-A11D7C6C-1972-42FC-8325-7885BADA1DB6Q33905188-628984A0-D355-4108-9DF0-E1CAF6C9376CQ33934294-604D1C13-C9EC-4818-B9D8-C8C74115893FQ33936717-156A8CDD-620A-43EF-A196-9D928F7ACFF7Q33987410-A5D2450F-21CF-4CAE-87AA-96801EB1D7DDQ33987538-2C68B55D-F2FC-42C8-BBBF-AA39095E8DCFQ34039477-B0D6CDA2-C6CA-4131-A57A-D6319C62A58DQ34092845-F3DB8793-5833-4748-A748-87E43CDA2E39Q34126697-590EB09F-3AD2-4935-ACCF-00779814F417Q34259469-0F675042-34C0-495F-ABAD-72629BC780F6Q34288498-1FFF7142-5289-4118-85B3-AFEAA4344FD8Q34289866-98FAD7AC-7ECE-4A57-BA1B-921CDEA80B43Q34312168-C2B976AC-4539-4DAC-B9C3-72994CAECEAAQ34420319-C12B5C17-7656-43FA-AA49-13CA9A2DB65AQ34478724-91AA11CF-FAD5-4555-80A7-35C8E1AE42FBQ34507126-A961D10B-206A-44A6-BB5D-A837A6AA6C17Q34529713-0EBF053D-D54A-4334-87F6-9E37490B88C8Q34779016-2093DB28-1799-4DD3-8127-1379E33FDEFEQ34780607-D4D904AB-C434-4889-AF64-C2F2A149746DQ34991389-5E173F3C-0101-412E-8303-78CBCE114BDDQ35101531-F21B9CB8-5A0D-4B7B-9869-CF4285345F49Q35192889-D1851EF1-667B-4087-B741-2E61E1FAA10AQ35226200-84F47802-0D88-4551-9443-994495B72C9FQ35339702-D2BBBE05-413B-4A4C-A56E-18167AE4758CQ35634159-ADFC18D4-67C7-4FCF-B34E-5F9F4C540710
P2860
Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Protective immunity to vaccini ...... lar and extracellular virions.
@en
Protective immunity to vaccini ...... lar and extracellular virions.
@nl
type
label
Protective immunity to vaccini ...... lar and extracellular virions.
@en
Protective immunity to vaccini ...... lar and extracellular virions.
@nl
prefLabel
Protective immunity to vaccini ...... lar and extracellular virions.
@en
Protective immunity to vaccini ...... lar and extracellular virions.
@nl
P2093
P2860
P1433
P1476
Protective immunity to vaccini ...... lar and extracellular virions.
@en
P2093
Christiana Fogg
Gary H Cohen
J Charles Whitbeck
Shlomo Lustig
P2860
P304
10230-10237
P356
10.1128/JVI.78.19.10230-10237.2004
P407
P577
2004-10-01T00:00:00Z